Healthcare/Pharmaceuticals Analyst Fadia, along with Dr. Joshua Cohen, Healthcare Analyst & Consultant at Joshua P. Cohen Healthcare Analytics, discuss the potential coverage implications for Biogen/Eisai’s Lecanemab should it get FDA approval on an Analyst/Industry conference call to be held on January 5 at 11 am.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ESALY:
- Needham health/pharmaceuticals analysts hold analyst/industry conference call
- Biogen’s Alzheimer’s Drug Could be Expensive
- Third trial death tied to Biogen and Eisai Alzheimer’s drug, Science reports
- Eisai initiates BLA submission of data for lecanemab in China
- Frontage partners with Eisai, Biogen to complete the Clarity AD study